Literature DB >> 32273145

Patients' understanding of oncology clinical endpoints: A literature review.

Vanessa Boudewyns1, Brian G Southwell1, Jessica T DeFrank1, Kate Ferriola-Bruckenstein1, Michael T Halpern1, Amie C O'Donoghue2, Helen W Sullivan3.   

Abstract

OBJECTIVES: Oncology clinical trials use a variety of clinical endpoints. Patients' understanding of the differences between clinical endpoints is important because misperceptions of treatment efficacy may affect treatment decisions. The objective of this literature review is to find and synthesize available empirical publications assessing patients' understanding of common oncology clinical endpoints.
METHODS: We conducted a literature search of 5 databases and 3 conferences, limiting the search to articles and abstracts published in English through September 2018. We reviewed the titles and abstracts for inclusion, then reviewed full texts to determine if they reported empirical research studies focused on (1) clinical endpoints, (2) oncology, and (3) patient understanding. The original search identified 497publications, of which 13 met the inclusion criteria.
RESULTS: Available literature yields little information on this topic.The few publications that do exist suggest that healthcare professionals and cancer patients generally do not discuss clinical endpoint concepts and that patients can be confused about the purpose of a treatment based on misperceptions about endpoints.
CONCLUSIONS: Research is needed on how to discuss oncology clinical endpoints with patients. PRACTICE IMPLICATIONS: Patient-friendly definitions of clinical endpoints may help healthcare providers communicate important information about treatments to patients. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical endpoints; Patient understanding; Patients; Progression-free survival; Regulatory science

Mesh:

Year:  2020        PMID: 32273145      PMCID: PMC7423743          DOI: 10.1016/j.pec.2020.03.018

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  16 in total

1.  Health literacy: what is it?

Authors:  Nancy D Berkman; Terry C Davis; Lauren McCormack
Journal:  J Health Commun       Date:  2010

2.  Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France.

Authors:  Christel Protiére; Rachel Baker; Dominique Genre; Anthony Goncalves; Patrice Viens
Journal:  Med Decis Making       Date:  2017-02-15       Impact factor: 2.583

3.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

4.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

Authors:  Chul Kim; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2016-05-10       Impact factor: 7.616

5.  Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.

Authors:  Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 6.  Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer.

Authors:  Robin Matsuyama; Sashidhar Reddy; Thomas J Smith
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

7.  Treatment priorities in oncology: do we want to live longer or better?

Authors:  Guilherme Nader Marta; Luís G Del Nero; Gustavo Nader Marta; Andrea Mangabeira; Gabriela Critchi; Maria J Kovács; João Luis Fernandes da Silva; Everardo D Saad
Journal:  Clinics (Sao Paulo)       Date:  2014-08       Impact factor: 2.365

8.  Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study.

Authors:  V Jenkins; V Farewell; S May; S Catt; L Matthews; V Shilling; J Dickson; R Simcock; L Fallowfield
Journal:  Support Care Cancer       Date:  2018-05-29       Impact factor: 3.603

9.  Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer.

Authors:  Janice Kim; Jennifer Gao; Laleh Amiri-Kordestani; Julia A Beaver; Paul Kluetz
Journal:  Oncologist       Date:  2019-05-16

10.  Class, race and ethnicity and information avoidance among cancer survivors.

Authors:  R F McCloud; M Jung; S W Gray; K Viswanath
Journal:  Br J Cancer       Date:  2013-05-16       Impact factor: 7.640

View more
  2 in total

1.  Patients' Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kate Ferriola-Bruckenstein; Janice P Tzeng; Vanessa Boudewyns
Journal:  Oncologist       Date:  2020-08-27

2.  Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study.

Authors:  Paola Mosconi; Anna Roberto; Nicoletta Cerana; Nicoletta Colombo; Florence Didier; Maurizio D'Incalci; Domenica Lorusso; Fedro Alessandro Peccatori
Journal:  J Ovarian Res       Date:  2022-04-14       Impact factor: 5.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.